Tal Medical said it won funding from the National Institute of Mental Health, allowing the company to conduct a clinical trial of its Low Field Magnetic Stimulation technology in treating depression.
The LFMS technology is a non-invasive neuromodulation system that delivers magnetic stimulation to the brain through an external electromagnetic coil.
The NIMH awarded the funding through its Rapidly Acting Treatments for Treatment Resistant Depression program, a new initiative dedicated to identifying and testing “promising anti-depressant interventions,” according to a press release.
The federal funding brings Tal Medical’s take to about $6 million in support of its trial, according to a spokesperson for PureTech Ventures, a life sciences venture capital group that helped launch Tal Medical in 2010.
The LMFS trial is funded on a contract between NIHMH and Massachusetts General Hospital, according to PureTech. The trial is a 90-patient, 6-site, sham-controlled study in patients who have responded negatively to 1-3 antidepressant treatments. In addition to MGH, the trial will also be run by Yale, Mount Sinai and Emory, among other leading hospitals.
“There is a well-documented lack of innovation in the field of antidepressant drug development and LFMS has the potential to break this paradigm and offer patients a clinical profile completely different from that of current therapies. The sham-controlled data with LFMS indicate an antidepressant response within minutes of patients receiving a single 20 minute LFMS treatment,” Tal Medical co-founder and chairman Dr. Steve Paul said in prepared remarks.
Building Better Companies at DeviceTalks Minnesota
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%! REGISTER NOW |
MassDevice Network
@MassDevice
LinkedIn
YouTube
Leave a Reply
You must be logged in to post a comment.